Nationale-Nederlanden Powszechne Towarzystwo Emerytalne’s Vertex Pharmaceuticals VRTX Stock Holding History

Nationale-Nederlanden Powszechne Towarzystwo Emerytalne’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-60,527	Closed	-$17.5M	–	29
2022 Q4	$17.5M	Buy	60,527 +1,436	+2%	+$438K	7.6%	3
2022 Q3	$17.1M	Buy	+59,091	New	+$17M	8.07%	2
2020 Q2	–	Sell	-61,500	Closed	-$14.6M	–	16
2020 Q1	$14.6M	Hold	61,500	–	–	16.09%	2
2019 Q4	$13.5M	Buy	+61,500	New	+$12.4M	11.75%	6

Other funds holding VRTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nationale-Nederlanden Powszechne Towarzystwo Emerytalne's VRTX Position: Q1 2023 in Review

Nationale-Nederlanden Powszechne Towarzystwo Emerytalne sold out of Vertex Pharmaceuticals (VRTX) in Q1 2023, closing a stake of 60,527 shares — an estimated $17.5M sold.

Nationale-Nederlanden Powszechne Towarzystwo Emerytalne first reported a position in VRTX in Q4 2019 and held it in 4 quarters. The position peaked at $17.5M in Q4 2022. 1,208 funds tracked by Wall St. Rank hold VRTX as of Q1 2023.

Nationale-Nederlanden Powszechne Towarzystwo Emerytalne reported no remaining Vertex Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Nationale-Nederlanden Powszechne Towarzystwo Emerytalne sold 60,527 Vertex Pharmaceuticals shares in Q1 2023, an estimated $17.5M.
Nationale-Nederlanden Powszechne Towarzystwo Emerytalne first reported a position in Vertex Pharmaceuticals in Q4 2019 and held it in 4 quarters.
Nationale-Nederlanden Powszechne Towarzystwo Emerytalne's Vertex Pharmaceuticals position peaked at $17.5M in Q4 2022.
1,208 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2023.

Based on Nationale-Nederlanden Powszechne Towarzystwo Emerytalne's 13F filing for Q1 2023, filed 17 May 2024.